A systematic approach that views the clinical research department as an integral part of the development team can enhance the likelihood of success in the creation of new products. Nancy J. Stark Many ...
Laboratory assessments — from preclinical research through post-marketing surveillance — determine whether a cell-based therapy for cancer succeeds or fails. “Every developer out there advancing CAR T ...
SAN DIEGO and SUZHOU, China, July 15, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...
Nanobiotix global development plan for first-in-class radioenhancer NBTXR3 across several solid tumor indications proceeds as planned with focus on priority pathways in head and neck cancer and ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat ...
There is a low probability of success for immuno-oncology (IO) research. There is a below average likelihood-of-approval rate for oncology, usually 5.3% vs. 7.9% for all indications. The clinical ...
Bari Kowal, Senior Vice President, Development Operations & Portfolio Management at Regeneron Clinical trial innovation is a hot topic, but it’s not a new one. The first fully virtual randomized trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback